Orchestra BioMed launches stock sale to fund two heart-device trials
What's the deal? Orchestra BioMed (Nasdaq: OBIO), a biomedical company that partners with large device makers, has commenced an underwritten public offering of common stock. All shares are being sold by the company, which also plans to grant underwriters a 30-day option to buy up to 15% more shares. The size and terms were not disclosed.
Where's the money going? Net proceeds, combined with existing cash, will fund its two flagship programs. That means AVIM Therapy, a pacemaker-delivered treatment for hypertension, and its BACKBEAT pivotal trial, plus the Virtue Sirolimus AngioInfusion Balloon program and its coronary trial. The rest covers other product candidates, working capital, and general corporate purposes.
Why now? The raise lands as both programs approach key milestones. The company said in October it had exceeded enrollment targets for BACKBEAT, with primary results targeted for a major conference in Q2 2027, while the Virtue SAB trial continues enrolling.
What's the context? Orchestra reported $110 million in cash and marketable securities at June 30, 2026, with runway projected into Q4 2027. That followed $35 million in strategic capital from MedtronicDealroom has a profile for this one. Try Dealroom → and Ligand earlier that quarter.
What could go wrong? The offering is subject to market conditions, and there is no assurance it will be completed or at what size. New shares would also dilute existing holders, and the 30-day underwriter option adds potential dilution.
Piper SandlerDealroom has a profile for this one. Try Dealroom → and TD Cowen are joint bookrunning managers, with BTIGDealroom has a profile for this one. Try Dealroom → acting as a bookrunner.
The signal: Raising fresh equity ahead of clinical readouts — rather than waiting on existing runway — signals Orchestra is moving to secure capital while its two cardiovascular programs head into their most closely watched stretch.
Read more: marketscreener.com
Image credit: USDAgov
